Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study) [0.03%]
度伐利尤单抗联合卡铂和依托泊苷治疗晚期肺大细胞神经内分泌癌的开放性前瞻性II期研究方案（LOGIK2401：NECTAR研究）
Hidenobu Ishii,Koichi Azuma,Fumiaki Kiyomi et al.
Hidenobu Ishii et al.
Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the lung is a rare histologic type and is placed in the neuroendocrine tumor category along with small cell lung cancer (SCLC) at the latest histologic classifi...
Bioinformatic-based study to investigate the fluctuations and performance of MYD88 and GRB2 gene expression in gastric cancer; Can they be considered diagnostic biomarkers? [0.03%]
基于生物信息学的胃癌MYD88和GRB2基因表达变化及功能分析研究；可否作为诊断标志物？
Seyed Mustafa Mirnezami,Saman Morovat,Afshin Shafaghi et al.
Seyed Mustafa Mirnezami et al.
Gastric cancer (GC) ranks as the fourth most prevalent malignancy and constitutes the second leading cause of cancer-related mortality globally. The elevated mortality rate is linked to molecular heterogeneity, late-stage diagnosis, and the...
Bradley J Monk,Manish R Patel,Sarper Toker et al.
Bradley J Monk et al.
The successful development of anticancer medicines is arduous and highly technical. Although clear to some, many sponsors are not aware of regulatory mandates and processes leading to delays and missed opportunities. Drug development begins...
Analysis of the relevant factors of lymph node metastasis in No.253 lymph node of rectal cancer patients [0.03%]
低位直肠癌患者第253淋巴结转移相关因素分析
Yu-Xi Gao,Shi-Xiang Pan,Fang Hu et al.
Yu-Xi Gao et al.
Objective: Lymph node metastasis is the primary metastasis of colorectal cancer, and it is of positive significance to explore the characteristics and potential influencing factors of lymph node metastasis in colorectal c...
Investigating the correlation between cytokine levels and prognostic factors in advanced gastric cancer: A systematic review and meta-analysis [0.03%]
胃癌晚期细胞因子水平与预后因素相关性系统评价和meta分析
Zakari Shaibu,Fumeng Yang,Zhihong Chen et al.
Zakari Shaibu et al.
Background: Advanced gastric cancer (AGC) aggressiveness and poor prognosis necessitate understanding its molecular drivers. Cytokines in the tumor microenvironment influence tumor behavior, and this study aims to analyze...
Clinicogenomic and treatment outcomes in RET fusion-positive NSCLC: A multicenter study in Latin American Hispanic patients [0.03%]
RET融合阳性NSCLC的临床基因组学和治疗结果：拉丁美洲西班牙裔患者的多中心研究
Oscar Arrieta,Andrés F Cardona,Nicolle Wagner-Gutiérrez et al.
Oscar Arrieta et al.
Background: RET fusions represent a rare but actionable molecular subtype in non-small cell lung cancer (NSCLC), comprising approximately 1 % of cases. Despite the availability of selective RET inhibitors (RETsi), data on...
Upregulation of FLT1 activates the TGF-β1/Smad3 pathway to promote iodide resistance in thyroid cancer [0.03%]
FLT1上调通过激活TGF-β1/Smad3信号通路促进碘抵抗在甲状腺癌中的作用
Jing Zhuang,Bo Huang,Jinyou Li et al.
Jing Zhuang et al.
Background: The identification of new therapeutic targets for patients with radioiodide resistance differentiated thyroid cancer (DTC) may help improve the prognosis for I131-resistant DTC patients. ...
A bibliometric analysis on KRAS, a targeted marker for blockbuster clinical drugs [0.03%]
一种关于KRAS的靶向标志物的重磅药物的文献计量分析
Zongzhen Guo,Shiqing Zhao,Yanfei Sun et al.
Zongzhen Guo et al.
This study aims to provide an overview of research hotspots and trends in KRAS, a key star gene which has been paid special attention to in the field of cancer. Publications on KRAS were searched in the Web of Science Core Collection databa...
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severity [0.03%]
2017年至2020年印尼乳腺癌流行趋势：按年龄和疾病严重程度的国家级分析
Sudewi Mukaromah Khoirunnisa,Didik Setiawan,Maarten J Postma et al.
Sudewi Mukaromah Khoirunnisa et al.
Introduction: Breast cancer is a leading cause of cancer-related disability-adjusted life years (DALYs) and the second most common cancer among Asian women, including in Indonesia. Its increasing burden necessitates a com...
Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study [0.03%]
阿美替尼对一线三代EGFR-TKI耐药的EGFR突变型NSCLC患者的再挑战治疗：一项倾向性匹配队列研究
Jiaqi Zhao,Maolin Liu,Siqing Liu et al.
Jiaqi Zhao et al.
Background: Overcoming resistance of first-line third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) remained a challenge. This study aimed to c...